NPPG Administrator, Suite 213, Boundary House, London W7 2QE
Recent consultations NPPG has responded to as of July 2025
Thank you to our committee members and our specialist interest groups for the comments received on recent consultations.
Since the previous full committee meeting the following consultations have been reviewed:
| NICE STA | Depemokimab for treating severe eosinophilic asthma in people 12 years and over, ID 6447 | 12/03/2025 | Deadline for comments is 09/04/2025 | Circulated to committee 12/03/2025 | Comments submitted from SukeshiM on 08/04/2025 |
| NICE STA | Vosoritide for treating achondroplasia in people 4 months and over, ID6488 | 14/03/2025 | Deadline for comments is 11/04/2025 | Circulated to committee 18/03/2025 | No comments received. A ‘No comment’ response submitted. |
| NICE STA | Sebetralstat for treating acute attacks of hereditary angioedema in people 12 years and over, ID6284 | 14/03/2025 | Deadline for expert nominations and comments is 27/05/2025 | Circulated to committee 18/03/2025 | No comments received. A ‘No comment’ response submitted. |
| NICE STA | Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over, ID 6221 | 20/03/2025 | Deadline for comments is 17/04/2025 | Circulated to committee 25/03/2025 | Comments submitted N Gooding 17/04/2025 |
| NICE STA | Low-dose atropine eye drops for treating myopia in people 3 to 14 years, ID6517 | 24/03/2025 | Deadline for comments is 23/04/2025 | Circulated to committee 25/03/2025 | No comments received. A ‘No comment’ response submitted. |
| PrescQipp | Registered for 2025-27 work plan stakeholder consultation | 24/03/2025 | Received notification email from NGooding. | Completed EoI form for PrescQIPP work plan 2025-2027 excluding topics for adults | |
| NICE | Draft guideline on pneumonia: diagnosis and management (update) | 09/04/2025 | Deadline for comments is 12/05/2025 | Circulated to committee on 10/04/2025 | Comments received from NGooding. Submitted. |
| NICE STA | Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over, ID 6497 | 11/04/2025 | Deadline for comments is 24/06/2025 | Circulated to committee on 16/04/2025 | No comments received. A ‘No comment’ response submitted. |
| NICE STA | Pegcetacoplan for treating primary complement 3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over, ID 6489 | 14/04/2025 | Deadline for comments is 15/05/2025 | Circulated to committee on 16/04/2025 | No comments received . A ‘No comment’ response submitted. |
| NICE STA | Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age, ID 6484 | 15/04/2025 | Deadline for comments is 16/05/2025 | Circulated to committee on 16/04/2025 | No comments received. A ‘No comment’ response submitted. |
| NICE MTA | Resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis with liver fibrosis, ID 6458 | 17/04/2025 | Deadline for comments is 20/05/2025 | Circulated to committee on 22/04/2025 | No comments received. A ‘No comment’ response submitted. |
| NHSE Spec Comm | Haemophilia and related bleeding disorders (adults and children). | Deadline for comments 19/06/2025 | Circulated, with copy of questions and direct response link, to committee 21/05/2025 | No comments received. | |
| NHSE Spec Comm | Obsessive-compulsive disorder and body dysmorphic disorder: assessment and management | Deadline Consultation 05/06/2025. Committee / lay member 09/06/2025 | Registered as stakeholder and then circulated to committee 21/05/2025 | No comments received. | |
| NHSE Spec Comm | lonafarnib for Hutchinson-Gilford progeria syndrome (12 months of age and over) [2402]. | 21/05/2025 | Deadline 04/06/2025 | Circulated, with copy of questions and direct response link, to committee 21/05/2025 | No comments received. |
| NICE Quality Standards | Invitation to attend NICE Indicators advisory committee – Tuesday 03 June 2025 | 4:00pm on 26/05/2025 | Circulated to committee members 21/05/2025 | ||
| NICE STA | Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441] | 11/06/2025 | Deadline for expert nomination, and submission: 12/08/2025 | Circulated to committee members 17/06/2025. | |
| NICE STA | Depemokimab for treating severe eosinophilic asthma in people 12 years and over, ID 6447 | 16/06/2025 | Deadline for comments; 12/08/2025 | Circulated to committee members 17/06/2025. |
CCA – Cost Comparison Appraisal; STA – Single Technology Appraisal; QSU – Quality Standard Update; SpecComm – Specialised Commissioning; MTA – Multiple Technology Appraisal; HTSE – Highly Specialised Technologies Evaluation.